When immunity therapy such as antibodies against programmed death protein 1 (PD-1) was not used for patients with metastatic NSCLC without sensitising EGFR/anaplastic lymphoma kinase (ALK) alterations, numberous prospective clinical studies[12-14] reported that three-dimensional radiotherapy combined with chemotherapy for primary tumor of stage IV NSCLC has the significance of prolonging survival rates. This evidence concerns the gene ALK and non-small cell lung carcinoma.